دورية أكاديمية
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
| العنوان: | Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. |
|---|---|
| المؤلفون: | Dankner M; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montréal, Québec, Canada.; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.; Faculty of Medicine, McGill University, Montréal, Québec, Canada., Wang Y; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.; Faculty of Medicine, McGill University, Montréal, Québec, Canada.; Department of Surgery, McGill University, Montréal, Québec, Canada.; Research Institute of the McGill University Health Centre, McGill University, Montréal, Québec, Canada., Fazelzad R; Library and Information Services, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada., Johnson B; The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Gastrointestinal Medical Oncology, Houston, TX., Nebhan CA; Vanderbilt University Medical Center, Nashville, TN., Dagogo-Jack I; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Myall NJ; Division of Oncology, Stanford University, Stanford, CA., Richtig G; Division of Oncology, Medical University of Graz, Graz, Austria., Bracht JWP; Quirón-Dexus University Institute, Barcelona, Spain., Gerlinger M; Barts Cancer Institute, Queen Mary University of London and St Bartholomew's Hospital, London, United Kingdom., Shinozaki E; Japanese Foundation for Cancer Research Cancer Institute Hospital, Tokyo, Japan., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Kotani D; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Fangusaro JR; Aflac Cancer Center, Emory University School of Medicine, Atlanta, GA., Gautschi O; University of Bern and Cantonal Hospital of Lucerne, Lucerne, Switzerland., Mazieres J; Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Sosman JA; Department of Medicine, Northwestern University, Chicago, IL., Kopetz S; The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Gastrointestinal Medical Oncology, Houston, TX., Subbiah V; The University of Texas MD Anderson Cancer Center, Houston, TX., Davies MA; The University of Texas MD Anderson Cancer Center, Houston, TX., Groover AL; BioMed Valley Discoveries, Kansas City, MO., Sullivan RJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Johnson DB; Vanderbilt University Medical Center, Nashville, TN., Benedetti A; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada., Cescon DW; Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Spreafico A; Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Zogopoulos G; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.; Faculty of Medicine, McGill University, Montréal, Québec, Canada.; Department of Surgery, McGill University, Montréal, Québec, Canada.; Research Institute of the McGill University Health Centre, McGill University, Montréal, Québec, Canada., Rose AAN; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montréal, Québec, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Oncology, McGill University, Montréal, Québec, Canada. |
| المصدر: | JCO precision oncology [JCO Precis Oncol] 2022 Aug; Vol. 6, pp. e2200107. |
| نوع المنشور: | Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2017]- |
| مواضيع طبية MeSH: | Lung Neoplasms*/drug therapy , Melanoma*/drug therapy, Humans ; Mitogen-Activated Protein Kinases/genetics ; Prospective Studies ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins B-raf/genetics ; United States |
| مستخلص: | Purpose: Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to molecular characteristics. Consensus treatment strategies for class 2 and 3 BRAF mutations have not yet been established. Methods: We performed a systematic review and meta-analysis with published reports of individual patients with cancer harboring class 2 or 3 BRAF mutations from 2010 to 2021, to assess treatment outcomes with US Food and Drug Administration-approved mitogen-activated protein kinase (MAPK) pathway targeted therapy (MAPK TT) according to BRAF class, cancer type, and MAPK TT type. Coprimary outcomes were response rate and progression-free survival. Results: A total of 18,167 studies were screened, identifying 80 studies with 238 patients who met inclusion criteria. This included 167 patients with class 2 and 71 patients with class 3 BRAF mutations. Overall, 77 patients achieved a treatment response. In both univariate and multivariable analyses, response rate and progression-free survival were higher among patients with class 2 compared with class 3 mutations, findings that remain when analyses are restricted to patients with melanoma or lung primary cancers. MEK ± BRAF inhibitors demonstrated greater clinical activity in class 2 compared with class 3 BRAF-mutant tumors than BRAF or EGFR inhibitors. Conclusion: This meta-analysis suggests that MAPK TTs have clinical activity in some class 2 and 3 BRAF-mutant cancers. BRAF class may dictate responsiveness to current and emerging treatment strategies, particularly in melanoma and lung cancers. Together, this analysis provides clinical validation of predictions made on the basis of a mutation classification system established in the preclinical literature. Further evaluation with prospective clinical trials is needed for this population. Competing Interests: Benny JohnsonConsulting or Advisory Role: Gritstone Bio, Incyte, Taiho Oncology, InsmedResearch Funding: Bristol Myers Squibb (Inst), Syntrix Biosystems (Inst) Ibiayi Dagogo-JackHonoraria: American Academic Health System, Total Health Conferencing, DAVA Oncology, Creative Educational Concepts, Medscape, ASCO Post, OncLive/MJH Life SciencesConsulting or Advisory Role: Boehringer Ingelheim, AstraZeneca, Xcovery, Catalyst Pharmaceuticals, Pfizer, Syros Pharmaceuticals, Novocure, BostonGene, Bayer, Genentech, Sanofi, JanssenResearch Funding: Pfizer (Inst), Array BioPharma (Inst), Novartis (Inst), Genentech (Inst), Calithera Biosciences (Inst), Vivace Therapeutics (Inst)Travel, Accommodations, Expenses: Pfizer, Array BioPharma Nathaniel J. MyallHonoraria: Patient Power Georg RichtigTravel, Accommodations, Expenses: Ipsen Marco GerlingerStock and Other Ownership Interests: VertexResearch Funding: Bristol Myers Squibb, Merck KGaA, Roche/Genentech Eiji ShinozakiHonoraria: Yakult Honsha, Merck Serono, Chugai Pharma, Takeda, Sanofi, Lilly, Taiho Pharmaceutical, Daiichi Sankyo/UCB Japan Takayuki YoshinoHonoraria: Chugai Pharma, Merck, Bayer Yakuhin, Ono Pharmaceutical, MSD K.K.Research Funding: MSD (Inst), Daiichi Sankyo Company, Limited (Inst), Ono Pharmaceutical (Inst), Taiho Pharmaceutical (Inst), Amgen (Inst), Sanofi (Inst), Pfizer (Inst), Genomedia (Inst), Sysmex (Inst), Nippon Boehringer Ingelheim (Inst), Chugai Pharma (Inst) Daisuke KotaniHonoraria: Takeda, Chugai Pharma, Lilly Japan, Merck Serono, Sysmex, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squibb Japan, MSD, Daiichi Sankyo/UCB JapanResearch Funding: Ono Pharmaceutical (Inst), MSD (Inst), Novartis (Inst), Janssen (Inst), IQvia (Inst), Syneos Health (Inst), CMIC (Inst) Jason R. FangusaroHonoraria: AstraZeneca, Pyramid BiosciencesConsulting or Advisory Role: Celgene, AstraZeneca Oliver GautschiConsulting or Advisory Role: Amgen (Inst), Lilly (Inst)Other Relationship: Bayer (Inst), Pfizer (Inst), Roche (Inst), Merck, Lilly Julien MazieresConsulting or Advisory Role: Novartis, Roche/Genentech, Pfizer, Bristol Myers Squibb, Lilly/ImClone, MSD, AstraZeneca, Pierre Fabre, Blueprint Medicines, Hengrui TherapeuticsResearch Funding: Roche (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst), Pierre Fabre (Inst)Travel, Accommodations, Expenses: Pfizer, Roche, Bristol Myers Squibb Jeffrey A. SosmanHonoraria: Jazz Pharmaceuticals, Apexian Pharmaceuticals, Iovance BiotherapeuticsConsulting or Advisory Role: Apexigen, Jazz Pharmaceuticals, Iovance Biotherapeutics Scott KopetzThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier MedicinesConsulting or Advisory Role: Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health, Pierre Fabre, Redx Pharma, Ipsen, Daiichi Sankyo, Natera, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, AbbVie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech, Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson/Janssen, Genomic Health, Frontier Medicines, Replimune, Taiho PharmaceuticalResearch Funding: Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyo Vivek SubbiahConsulting or Advisory Role: MedImmune, Helsinn Therapeutics, Loxo, R-Pharm, QED TherapeuticsResearch Funding: Novartis (Inst), GlaxoSmithKline (Inst), NanoCarrier (Inst), Northwest Biotherapeutics (Inst), Genentech/Roche (Inst), Berg Pharma (Inst), Bayer (Inst), Incyte (Inst), Fujifilm (Inst), PharmaMar (Inst), D3 Oncology Solutions (Inst), Pfizer (Inst), Amgen (Inst), AbbVie (Inst), Multivir (Inst), Blueprint Medicines (Inst), LOXO (Inst), Vegenics (Inst), Takeda (Inst), Alfasigma (Inst), Agensys (Inst), Idera (Inst), Boston Biomedical (Inst), Inhibrx (Inst), Exelixis (Inst), Turning Point Therapeutics (Inst)Travel, Accommodations, Expenses: PharmaMar, Bayer, Novartis, Helsinn TherapeuticsOther Relationship: Medscape Michael A. DaviesConsulting or Advisory Role: Genentech/Roche, Novartis, Bristol Myers Squibb, NanoString Technologies, Array BioPharma, Apexigen, Pfizer, Eisai, ABM, Iovance BiotherapeuticsResearch Funding: GlaxoSmithKline (Inst), Genentech/Roche (Inst), AstraZeneca (Inst), Merck (Inst), Oncothyreon (Inst), Myriad Genetics (Inst), Sanofi (Inst), Pfizer (Inst), ABM (Inst), LEAD (Inst) Anna L. GrooverEmployment: BioMed Valley Discoveries Ryan J. SullivanConsulting or Advisory Role: Novartis, Merck, Replimune, Asana Biosciences, Alkermes, Eisai, Pfizer, Iovance Biotherapeutics, OncoSec, AstraZeneca, Bristol Myers SquibbResearch Funding: Amgen (Inst), Lilly (Inst), BioMed Valley Discoveries (Inst), Merck (Inst), Deciphera (Inst), Roche/Genentech (Inst), Moderna Therapeutics (Inst), Sanofi (Inst), Aeglea Biotherapeutics (Inst), Asana Biosciences (Inst), Viralytics (Inst), Compugen (Inst), Neon Therapeutics (Inst), Pfizer (Inst), BeiGene (Inst), Rubius Therapeutics (Inst), Strategia (Inst) Keith T. FlahertyStock and Other Ownership Interests: Clovis Oncology, Loxo, X4 Pharma, Strata Oncology, PIC Therapeutics, Apricity Health, Oncoceutics, FOGPharma, Tvardi Therapeutics, Checkmate Pharmaceuticals, Kinnate Biopharma, Scorpion Therapeutics, ALX Oncology, xCures, Monopteros Therapeutics, Vibliome Therapeutics, Transcode Therapeutics, Soley Therapeutics, Nextech InvestConsulting or Advisory Role: Novartis, Lilly, Oncoceutics, Tvardi Therapeutics, Takeda, Debiopharm Group, OmRx Douglas B. JohnsonConsulting or Advisory Role: Bristol Myers Squibb, Merck, Novartis, Iovance Biotherapeutics, Catalyst Pharmaceuticals, Oncosec, Pfizer, Mosaic ImmunoEngineering, Targovax, MallinckrodtResearch Funding: Incyte, Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy David W. CesconConsulting or Advisory Role: Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Merck, Roche/Genentech, Exact Sciences, Gilead Sciences, EisaiResearch Funding: Merck (Inst), Roche/Genentech (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Inivata (Inst), AstraZeneca (Inst), Gilead Sciences (Inst)Patents, Royalties, Other Intellectual Property: Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore-associated complex subunit 3 (ska3) geneUncompensated Relationships: Inivata Anna SpreaficoHonoraria: Bristol Myers Squibb, Medison & ImmunocoreConsulting or Advisory Role: Novartis, Merck, Bristol Myers Squibb, Oncorus, Medison & ImmunocoreResearch Funding: Bristol Myers Squibb, Novartis, Merck, Symphogen, AstraZeneca/MedImmune, Bayer, Surface Oncology, Janssen Oncology, Northern Biologics, Replimune, Roche, Alkermes, Array BioPharma, GlaxoSmithKline, Treadwell Therapeutics (Inst), Amgen (Inst)Travel, Accommodations, Expenses: Merck, Bristol Myers Squibb, Idera, Bayer, Janssen Oncology, Roche George ZogopoulosPatents, Royalties, Other Intellectual Property: TC-PTP inhibitors as APC activators for immunotherapyTravel, Accommodations, Expenses: Baxalta April A.N. RoseEmployment: Merck (I)Stock and Other Ownership Interests: Merck (I)Consulting or Advisory Role: PfizerNo other potential conflicts of interest were reported. |
| References: | Cancer Res. 2008 Nov 1;68(21):8673-7. (PMID: 18974108) Ann Intern Med. 2009 Aug 18;151(4):264-9, W64. (PMID: 19622511) N Engl J Med. 2012 Jul 12;367(2):107-14. (PMID: 22663011) Target Oncol. 2020 Oct;15(5):567-577. (PMID: 32889679) ESMO Open. 2020;5(1):e000624. (PMID: 33551068) N Engl J Med. 2021 Jun 24;384(25):2371-2381. (PMID: 34096690) J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359. (PMID: 33724754) N Engl J Med. 2015 Jan 1;372(1):30-9. (PMID: 25399551) Eur J Cancer. 2016 Jul;62:132-7. (PMID: 27189322) Lancet Oncol. 2017 Apr;18(4):435-445. (PMID: 28284557) Lancet Oncol. 2020 Sep;21(9):1234-1243. (PMID: 32818466) Nat Rev Cancer. 2017 Nov;17(11):676-691. (PMID: 28984291) Nature. 2017 Aug 10;548(7666):234-238. (PMID: 28783719) Cancer Discov. 2021 Jul;11(7):1716-1735. (PMID: 33568355) J Natl Compr Canc Netw. 2021 Apr 1;19(4):364-376. (PMID: 33845460) J Clin Oncol. 2019 Jun 10;37(17):1460-1469. (PMID: 30892987) Lancet. 2015 Aug 1;386(9992):444-51. (PMID: 26037941) Clin Cancer Res. 2018 Dec 15;24(24):6483-6494. (PMID: 29903896) Oncologist. 2021 Sep;26(9):731-e1498. (PMID: 33861486) J Can Health Libr Assoc. 2014;35:16-23. (PMID: 26793244) Lancet Oncol. 2015 Oct;16(13):1389-98. (PMID: 26433819) Nature. 2011 Nov 23;480(7377):387-90. (PMID: 22113612) Cancer Cell. 2019 Jul 8;36(1):35-50.e9. (PMID: 31287991) Cancer Cell. 2016 Apr 11;29(4):477-493. (PMID: 26996308) J Clin Oncol. 2013 Jul 1;31(19):e324-6. (PMID: 23715574) N Engl J Med. 2019 Oct 24;381(17):1632-1643. (PMID: 31566309) Nat Chem Biol. 2020 Nov;16(11):1170-1178. (PMID: 32778845) Lancet Oncol. 2016 Sep;17(9):1248-60. (PMID: 27480103) JCO Precis Oncol. 2019 Aug 5;3:. (PMID: 32914034) Int J Cancer. 2016 Feb 15;138(4):881-90. (PMID: 26314551) Cancer Discov. 2014 Jan;4(1):94-109. (PMID: 24265153) Ann Oncol. 2015 May;26(5):894-901. (PMID: 25722381) Oncotarget. 2016 Aug 26;8(36):60094-60108. (PMID: 28947956) Cancer Discov. 2019 Mar;9(3):329-341. (PMID: 30770389) Cancer Res. 2011 Apr 1;71(7):2750-60. (PMID: 21317224) Cell. 2004 Mar 19;116(6):855-67. (PMID: 15035987) Eur J Cancer. 2020 Feb;126:33-44. (PMID: 31901705) Oncogene. 2018 Jun;37(24):3183-3199. (PMID: 29540830) Mol Cancer Ther. 2012 Apr;11(4):909-20. (PMID: 22389471) Nat Struct Mol Biol. 2015 Jan;22(1):37-43. (PMID: 25437913) Clin Cancer Res. 2013 Sep 1;19(17):4868-78. (PMID: 23833299) Cell Rep. 2022 Apr 5;39(1):110634. (PMID: 35385748) Clin Cancer Res. 2019 Dec 1;25(23):7089-7097. (PMID: 31515458) Cancer Discov. 2012 Sep;2(9):791-7. (PMID: 22798288) Lancet Oncol. 2016 Jul;17(7):984-993. (PMID: 27283860) JCO Precis Oncol. 2018 Nov;2:1-12. (PMID: 35135170) Clin Cancer Res. 2020 Apr 15;26(8):1812-1819. (PMID: 31924734) Cancer Cell. 2015 Sep 14;28(3):370-83. (PMID: 26343582) Lancet Oncol. 2017 Oct;18(10):1307-1316. (PMID: 28919011) |
| معلومات مُعتمدة: | P50 CA221703 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Protein Kinase Inhibitors) EC 2.7.11.1 (BRAF protein, human) EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) EC 2.7.11.24 (Mitogen-Activated Protein Kinases) |
| تواريخ الأحداث: | Date Created: 20220817 Date Completed: 20220819 Latest Revision: 20231003 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10530862 |
| DOI: | 10.1200/PO.22.00107 |
| PMID: | 35977349 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!